Last reviewed · How we verify

Injection of Cyclosporin

Hospices Civils de Lyon · Phase 3 active Small molecule

Injection of Cyclosporin is a Calcineurin inhibitor Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 3 development for Prevention of organ rejection in transplant recipients, Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis). Also known as: Cyclosporin A (CicloMulsion, verum).

Cyclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

Cyclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients, Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis).

At a glance

Generic nameInjection of Cyclosporin
Also known asCyclosporin A (CicloMulsion, verum)
SponsorHospices Civils de Lyon
Drug classCalcineurin inhibitor
TargetCalcineurin (protein phosphatase 2B)
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Cyclosporin binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The injectable formulation allows systemic immunosuppression for transplant rejection prevention and severe autoimmune conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Injection of Cyclosporin

What is Injection of Cyclosporin?

Injection of Cyclosporin is a Calcineurin inhibitor drug developed by Hospices Civils de Lyon, indicated for Prevention of organ rejection in transplant recipients, Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis).

How does Injection of Cyclosporin work?

Cyclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.

What is Injection of Cyclosporin used for?

Injection of Cyclosporin is indicated for Prevention of organ rejection in transplant recipients, Severe autoimmune conditions (e.g., severe rheumatoid arthritis, severe atopic dermatitis).

Who makes Injection of Cyclosporin?

Injection of Cyclosporin is developed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

Is Injection of Cyclosporin also known as anything else?

Injection of Cyclosporin is also known as Cyclosporin A (CicloMulsion, verum).

What drug class is Injection of Cyclosporin in?

Injection of Cyclosporin belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Injection of Cyclosporin in?

Injection of Cyclosporin is in Phase 3.

What are the side effects of Injection of Cyclosporin?

Common side effects of Injection of Cyclosporin include Nephrotoxicity, Hypertension, Tremor, Gingival hyperplasia, Hirsutism, Infection.

What does Injection of Cyclosporin target?

Injection of Cyclosporin targets Calcineurin (protein phosphatase 2B) and is a Calcineurin inhibitor.

Related